Funding was provided by the Australian National Health and Medical Research Council under Program Grant #487922, and NHMRC Project Grant #234709. We acknowledge the NHMRC-funded Australian Proteomics Computational Facility (APCF) under Enabling Grant #381413. This work was supported, in part, by funds from the Operational Infrastructure Support Program provided by the Victorian Government, Australia. We acknowledge the Australian Cancer Research Foundation for providing funds to purchase the Orbitrap (TM) mass spectrometer. Andrew M. Scott and Terrance G. Johns are inventors on patents for mAb806.